SCHEMBL600452

SCHEMBL600452

CCOC1CCC(C)(N2CCC(n3c(=O)[nH]c4cc(Cl)c(C)cc43)CC2)CC1

nearest known ligand 0.68

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
CHRM4 P08173 13/20 0.68
CHRM5 P08912 13/20 0.68
CHRM1 P11229 13/20 0.68
CHRM3 P20309 12/20 0.68
CHRM2 P08172 11/20 0.68
OPRM1 P35372 6/20 0.45
HTR1A P08908 1/20 0.42
ADRA2A P08913 1/20 0.42
DRD2 P14416 1/20 0.42
HTR2A P28223 1/20 0.42
SLC6A4 P31645 1/20 0.42
DRD3 P35462 1/20 0.42
KCNH2 Q12809 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL600451 1.00 CHRM4 (0.68) CHRM4CHRM5CHRM1CHRM3CHRM2
Hydrochloric Acid SCHEMBL600782 0.99 CHRM4 (0.67) CHRM4CHRM5CHRM1CHRM3CHRM2
Hydrochloric Acid SCHEMBL600781 0.99 CHRM4 (0.67) CHRM4CHRM5CHRM1CHRM3CHRM2
SCHEMBL601535 0.93 CHRM4 (0.80) CHRM4CHRM5CHRM1CHRM3CHRM2
SCHEMBL601534 0.93 CHRM4 (0.80) CHRM4CHRM5CHRM1CHRM3CHRM2
SCHEMBL603737 0.93 CHRM4 (0.80) CHRM4CHRM5CHRM1CHRM3CHRM2
SCHEMBL601748 0.92 CHRM4 (0.73) CHRM4CHRM5CHRM1CHRM3CHRM2
SCHEMBL601747 0.92 CHRM4 (0.73) CHRM4CHRM5CHRM1CHRM3CHRM2
Hydrochloric Acid SCHEMBL602806 0.92 CHRM4 (0.79) CHRM4CHRM5CHRM1CHRM3CHRM2
Hydrochloric Acid SCHEMBL602805 0.92 CHRM4 (0.79) CHRM4CHRM5CHRM1CHRM3CHRM2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1996188-B1 BENZIMIDAZOLES WHICH HAVE ACTIVITY AT M1 RECEPTOR AND THEIR USES IN MEDICINE GLAXO GROUP LTD (GB) 2013-05-15 EP claimed
US-20120309789-A1 Compounds which have activity at M1 receptor and their uses in medicine GLAXO GROUP LIMITED 2012-12-06 US claimed
US-20120041027-A1 BENZIMIDAZOLES WHICH HAVE ACTIVITY AT M1 RECEPTOR AND THEIR USES IN MEDICINE GLAXO GROUP LIMITED 2012-02-16 US claimed
US-20100190825-A1 BENZIMIDAZOLES WHICH HAVE ACTIVITY AT M1 RECEPTOR AND THEIR USES IN MEDICINE COOPER DAVID GWYN 2010-07-29 US claimed
EP-1996188-B1 BENZIMIDAZOLES WHICH HAVE ACTIVITY AT M1 RECEPTOR AND THEIR USES IN MEDICINE GLAXO GROUP LTD (GB) 2013-05-15 EP disclosed
US-20120309789-A1 Compounds which have activity at M1 receptor and their uses in medicine GLAXO GROUP LIMITED 2012-12-06 US disclosed
US-20120041027-A1 BENZIMIDAZOLES WHICH HAVE ACTIVITY AT M1 RECEPTOR AND THEIR USES IN MEDICINE GLAXO GROUP LIMITED 2012-02-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100190825-A1 BENZIMIDAZOLES WHICH HAVE ACTIVITY AT M1 RECEPTOR AND THEIR USES IN MEDICINE CHRM1, CHRM2, CHRM4 CHRM4 3/4885CHRM5 4/4885CHRM1 1/4885
US-20120041027-A1 BENZIMIDAZOLES WHICH HAVE ACTIVITY AT M1 RECEPTOR AND THEIR USES IN MEDICINE CHRM1, CHRM2, CHRM4 CHRM4 3/4885CHRM5 4/4885CHRM1 1/4885
US-20120309789-A1 Compounds which have activity at M1 receptor and their uses in medicine CHRM1, CHRM2, CHRM5 CHRM4 4/4885CHRM5 3/4885CHRM1 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.